-
Microbial Genomics: Oral bacteria cause enteritis
Time of Update: 2020-11-07
Nov 1, 2020/--- A study led by the University of New South Wales in Sydney found that severe ulcerative colitis, an inflammatory bowel disease (IBD), is linked to a newly discovered strain of oral bacteria.
-
JEM key proteins help promote memory B cell formation
Time of Update: 2020-11-07
Nov 1, 2020 /--- -- Signals from two key proteins are critical to the survival of our "immune memory," according to a new study published in the journal Of Animal Medicine by scientists at the Francis Crick Institute.
-
Plos One: Multiracial societies are more likely to produce group immunity
Time of Update: 2020-11-07
researchers at the Max Planck Institute for Complex Systems Physics in Lesun, Germany, used a new model to show that group immunity can be achieved at lower thresholds if some people are more susceptible to infection than others.
-
IJCP: Effects of smoking on psoriasis patients
Time of Update: 2020-11-07
November 1, 2020 /--- According to a study published online October 14 in the International Journal of Clinical Practice, smoking has negative effects on psoriasis, including increased incidence of nail injury and cardiovascular disease, as well as a higher psoriasis area and severity index.
-
Arthritis drug JAK inhibitor Baricitinib treats baldness: patients get significant improvement
Time of Update: 2020-11-06
Lilly and Incyte have announced new data on the treatment of baldness by JAK inhibitor Baricitinib (OLUMIANT).
the ongoing Phase 2/3 BRAVE-AA1 study evaluated the safety and effectiveness of Baricitinib in adult bald patients.
-
BMJ: Have immunosuppressant side effects? Scientists have found that Treg cells suppress immunity!
Time of Update: 2020-11-06
analysis of biomarkers in patients in the nTreg treatment group and control group, this study shows that this nTreg is safer, has good tolerance, and can reduce the use of immunosuppressants.
-
J Thromb Haemost: Analysis of devasalban efficacy in patients with antiphospholipid syndrome
Time of Update: 2020-11-06
researchers compared devassalban with huafarin to prevent thromboembolism events, haemorrhage and vascular death in high-risk triple-positive antiphospholipid syndrome patients.
patients who were randomly grouped to devasalban were transferred to huafarin therapy.
115 follow-up data were available in 120 randomly grouped patients.
-
Gastroenterology: Effects of different clinical remission criteria on recurrence rates in patients with ulcerative colitis
Time of Update: 2020-11-06
This study is a systematic review of the UC adult queue study, which reported the relative and absolute risk of clinical recurrence of UC patients achieving different treatment goals based on MES (0vs1), histological disease activity, and endoscopic results.
-
Head-to-head Phase 3 clinically confirmed that the treatment of moderate to severe psoriasis with anti-IL-17 monoantigen Bimekizumab was better than TNF monoantigen
Time of Update: 2020-11-06
results showed that at the 16th week of treatment, 86.2% of patients treated with bimekizumab had almost skin loss (PASI 90), while 47.2% of patients treated with Adamo monoantigen (p .lt;0.001).
-
Supplement C5a-subject selective inhibitor Avacopan treated sweat adenitis (HS): Phase II clinical trials yielded positive results
Time of Update: 2020-11-06
end of the treatment was the proportion of patients who had reached the clinical response to purulent sweat adenitis (HiSCR) after 12 weeks of treatment.
results showed that patients in the 30 mg avacopan group had a statistically higher response than placebos in Hurley III (severe) HS patients.
-
Sci Transl Med: Scientists have successfully engineered common yeasts to treat Thyrobacter difficile infections
Time of Update: 2020-11-05
November 3, 2020 // -- In a recent study published in the international journal Science Translational Medicine, scientists from the University of Maryland and other institutions studied mice and found that modifying common types of yeast in a specific way may be effective In the paper, the researchers describe how the specific antibodies produced by Saccharomyces boulardii are used to tohom the toxins produced by modifying Saccharomyces boulardii, while the researchers also describe how and how this particular antibody works.
-
JCI: Scientists have discovered a new potential target for treating autoimmune diseases!
Time of Update: 2020-11-04
Therefore, controlling the number and activity of Tregs is particularly important for maintaining the health of the body; in a recent study published in the international journal Journal of Clinical Investigation, scientists from institutions such as the University of Pennsylvania found that by targeting molecules called DEL-1 or as an effective way to help treat inflammation or suppress autoimmune responses, DEL-1 molecules promote Tregs and its immunosuppressive activity.
-
PNAS: Scientists have revealed the difference between pathogenic gene mutations and benign gene mutations
Time of Update: 2020-11-04
The function of protein is closely related to its three-dimensional structure, and in this study, the researchers identified and compared the protein properties of amino acids affected by pathogenic and benign error mutations, which are frequently mutated in pathogenic mutations compared to benign mutations (3-D mutation hot spots), which are important for protein adaptability and can also help explain pathogenic molecular determinants.
-
Nat Biomed Engine: Heavy! Chinese scientists have developed a new precision-treated leukemia vaccine
Time of Update: 2020-11-02
October 19, 2020 // -- In a recent study published in the international journal Nature Biomedical Engineering, scientists from the Institute of Process Engineering of the Chinese Academy of Sciences a
-
Nat Immunol: Scientists have created the first complete map that reveals how immune cells fight off and "remember" infections in the body
Time of Update: 2020-11-02
The results are expected to help scientists delve deeper into specific types of immune cells to develop new vaccines and therapies for a range of diseases, such as CD4-T cells, that are critical to the body's immunity, as the study is the first to develop a complete dynamic map of immune cells learning to fight microbial infections and subsequently preserve memory for future infections.
-
Angiogenesis: Revealing the molecular mechanisms by which the BMP6 protein regulates the formation of new blood vessels in the body promises to help develop new cardiovascular disease therapies
Time of Update: 2020-11-02
Protein 6 (BMP6, bone morphogenetic factor 6) may regulate the formation of blood vessels in the body through vascular endodertic growth factors 2 (VEGFR2) and Hippo signaling pathfages, and the findings are expected to help scientists develop new treatments for cardiovascular disease.
-
New drugs for special dermatitis! Sanofi Dupixent ® (Dabito®) is recommended by the European Union for the treatment of children aged 6-11 years, listed in China for the treatment of adults!
Time of Update: 2020-11-02
October 17, 2020 // -- Sanofi and Regeneron have jointly announced that the European Medicines Agency (EMA) Commission on Human Pharmaceutical Products (CHMP) has released An active review recommended approval of the expansion of Dupixent (Chinese product names: Dabito, generic name: dupilumab, dupilumab, dupilumab) for the treatment of children aged 6-11 with moderate to severe endemic dermatitis (AD) suitable for system therapy.
-
New drug for psoriasis! The Johnson il-23 inhibitor Tremfya (Tenoya ®) has been used continuously for 5 consecutive years and has shown high efficacy, and China has been listed!
Time of Update: 2020-11-02
October 16, 2020 // -- Johnson and Johnson (JNJ)'s Jansen Pharmaceuticals recently announced the anti-inflammatory drug Tremfya (Tenoya ®, common name: guselkumab, Gusekumab) treatment of moderate to severe adult patients phase 3 VOYAGE 1 study of new open label expansion data, showing that Tremfya treatment showed a high rate of skin loss removal, treatment in the last 5 years found no new safety signals.
-
JEM: Reveals the molecular mechanisms by which the body produces memory B cells and maintains a long-lasting immune response
Time of Update: 2020-11-02
In a study published in the international journal Journal of Student Medicine, scientists from Osaka University in Japan and other institutions have shown that the body's ability to react to infection again requires a protein called Bach2, which regulates the expression of special genes that guide the transformation of active B cells into memory B cells under selective conditions.
-
Nature: Scientists have analyzed 97,691 genomes to reveal the genetic causes of the cloning process!
Time of Update: 2020-11-02
October 19, 2020 // -- Scientists from Massachusetts General Hospital and other institutions have revealed the genetic causes of clone-induced hematopoiesis by analyzing the entire genome of 97,691 in
